Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment.

Chen S, Wang X, Jin Y, Chen X, Song Q, Wei G, Li L

Diabetes, metabolic syndrome and obesity : targets and therapy13 Mar 2024Cited by 12 (Europe PMC)

PMID38505539PMCIDPMC10949166DOI10.2147/dmso.s443631PepBankPUB-38505539

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, body weight fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to lower body weight than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 70
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553901
02HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, visceral fat area fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to less visceral fat than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseVisceral fat area
Study
n = 70
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553902
03HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, body fat fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to less body fat than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody fat
Study
n = 70
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553903
04HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, lean body mass fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to less lean body mass than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLean body mass
Study
n = 70
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553904
05HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, skeletal muscle mass fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to less skeletal muscle mass than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSkeletal muscle mass
Study
n = 70
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553905
06HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, water content fell after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to lower water content than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWater content
Study
n = 70
Outcome group
Body composition · Whole body
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553906
07HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, lean body mass percentage increased after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to higher lean body mass percentage than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLean body mass percentage
Study
n = 70
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The lean body mass percentage (LBMP) and skeletal muscle mass percentage (SMMP) significantly increased.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553907
08HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, skeletal muscle mass percentage increased after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, dulaglutide treatment was linked to higher skeletal muscle mass percentage than before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSkeletal muscle mass percentage
Study
n = 70
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
The lean body mass percentage (LBMP) and skeletal muscle mass percentage (SMMP) significantly increased.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553908
09HumanObservational studyEfficacy outcome
In overweight or obese adults with diabetes, bone mineral quality did not change significantly after dulaglutide treatment.
In plain wordsIn overweight or obese adults with diabetes, bone mineral quality did not change significantly from before dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBone mineral quality
Study
n = 70
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Moreover, there was no significant difference in bone mineral quality (BMQ) after the intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
Report a problemFND-3850553909

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
In dulaglutide-treated adults with diabetes, percentage body fat change was independently linked to percentage HbA1c change.
In plain wordsIn adults with diabetes receiving dulaglutide, percentage body fat change was independently linked to percentage HbA1c change.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAssociation of body fat and HbA1c changes
Study
n = 70
Outcome group
Glycemic control · Metabolic and weight
Measurements
Regression coefficient
0.449 beta
percentage body fat change versus percentage HbA1c change
Source sentences
Summary
The multiple linear regression model revealed that the % change in BF was independently associated with % change in HbA1c (β = 0.449, t = 3.148, p=0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included.
Summary · context
Changes in clinical indicators and body composition of patients before and after intervention were also analyzed.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3850553910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.